In the last week, Furiex Pharmaceuticals (NASDAQ:FURX) soared 135% after its diarrhea drug proved statistically significant in two Phase 3 trials that enrolled 2,428 patients. As a result, Furiex will seek FDA approval in the next quarter, and European approval within the next year. Furiex's drug, Eluxadoline, will treat diarrhea-predominant irritable bowel syndrome (IBS-d), a disease that effects 28 million people in the U.S. and in Europe combined. Therefore, Furiex has a lot of options as it plans to market Eluxadoline: It could market alone, find a partner, or be acquired, but what's the best plan of action for investors?
Going solo or finding a partner, which is best?
There's no denying that Furiex has a lot of...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|